Mario Polywka

Forge Therapeutics, Inc. manufactures pharmaceutical products. It is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins. The company was founded by Zachary A. Zimmerman, Seth Cohen and David Puerta and is headquartered in San Diego, CA.

Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom.

Part of Evotec SE, Aptuit (Oxford) Ltd. is a British pharmaceutical company that manufactures pharmaceutical products. The company is based in Abingdon, UK.

Part of Evotec SE, Evotec (UK) Ltd. provides research and development on natural sciences and engineering. The company is based in Abingdon, UK and was founded in 1991.

Part of Evotec SE, Evotec (München) GmbH is a German company that provides manufacturing and research support services for pharmaceutical and biotechnology companies. The company is based in Neuried, Germany. The CEOs are Dirk Ullmann, Loëtitia Edith Rouxel. The company was founded in 2005 by Axel Ullrich, Hellmut Kirchner, Henrik Daub. Evotec (München was acquired by Evotec SE on April 19, 2011 for $20.40 million.

Evotec International GmbH develops and provides drugs for the treatment of CNS disorders. It focuses on Alzheimer's disease and other neurological disorders. The company was founded in 1999 and is headquartered in Hamburg, Germany.

Orbit Discovery Ltd. develops technology for discovery process and drug development. The company was founded by Terry Rabbitts and Graham Ogg and is headquartered in Oxford, the United Kingdom.

Blacksmith Medicines, Inc. is a pharmaceutical company based in San Diego, CA and has subsidiaries in the United States. Blacksmith Medicines is focused on developing medicines that target metal-dependent enzymes found in human physiology. The company's platform combines a focused library of metal-binding pharmacophores with proprietary computational modeling approaches to rapidly and rationally design small molecule inhibitors that interact with key metal ions in the enzymes active site. The company recognized a large unmet need for new chemical matter and innovative approaches to drug this important class of enzymes. The company was founded by Zachary A. Zimmerman and has been led by him as the CEO since incorporation.